A review of new hormonal therapies for prostate cancer in black men: is there enough data?

Autor: Pascal Blanchet, Thierry Lebret, Matthias E Meunier, Laurent Brureau, Yann Neuzillet
Přispěvatelé: Hôpital Foch [Suresnes], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pointe-à-Pitre/Abymes [Guadeloupe], HAL UR1, Admin, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Oncology
Cancer Research
[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
MESH: African Americans / statistics & numerical data
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
Surgical oncology
Apalutamide
030212 general & internal medicine
Prospective cohort study
Abiraterone
Prostate Cancer
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
3. Good health
Survival Rate
030220 oncology & carcinogenesis
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
MESH: Survival rate
Research Article
medicine.medical_specialty
Antineoplastic Agents
Hormonal
MESH: Prostatic Neoplasmes / drug therapy
[SDV.CAN]Life Sciences [q-bio]/Cancer
Hormonotherapy
lcsh:RC254-282
MESH: Prognosis
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
Internal medicine
Genetics
medicine
Enzalutamide
Humans
MESH: Antineoplastic Agents
Hormonal / therapeutic use
Black men
MESH: Humans
business.industry
Prostatic Neoplasms
medicine.disease
[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
MESH: Male
Black or African American
Androgen receptor
chemistry
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
business
MESH: Postatic Neoplasmes / pathology
Hormone
Zdroj: BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.61. ⟨10.1186/s12885-020-07780-7⟩
BMC Cancer, 2021, 21 (1), pp.61. ⟨10.1186/s12885-020-07780-7⟩
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
ISSN: 1471-2407
Popis: Background Prostate cancer among black men is known to have specific molecular characteristics, especially the androgen receptor or enzymes related to the androgen metabolism. These targets are keys to the action of new hormonal therapies. Nevertheless, literature has a lack of data regarding black men. We aimed to gather the available literature data on new hormonal therapies among black populations. Methods We conducted a literature review from the PubMed / MEDLINE database until October 2020. All clinical studies of new hormonal therapies and black populations, regardless of methodology, were included. Results Four studies provided data on new hormonal therapies in black populations. Three studies reported a PSA decline in black patients treated with Abiraterone, higher in black men than in white men. Overall survival also appears to be higher in black patients treated with Abiraterone only or first. Conclusion Few articles have evaluated the effectiveness and safety of use of these treatments among black populations. The first results seem to show that Abiraterone can provide a benefit in overall survival in black populations. Prospective studies are needed to answer these questions in the future.
Databáze: OpenAIRE
Externí odkaz: